These studies were designed to determine whether the insulin resistance of fasting extends to its antilipolytic effects and whether fasting enhances the lipolytic effects of adrenergic stimulation independent of changes in plasma hormone and substrate concentrations. Palmitate flux was determined isotopically ([1-14C]palmitate) before and during epinephrine infusion in normal volunteers after a 14-h (day 1) and an 84-h (day 4) fast. Using a pancreatic clamp, constant plasma hormone and glucose concentrations were achieved on both study days in seven subjects. Six subjects were infused with saline and served as controls. During the pancreatic clamp, palmitate flux was greater (P less than 0.01) on day 4 than day 1, despite similar plasma insulin, glucagon, growth hormone, cortisol, epinephrine, norepinephrine, and glucose concentrations. The lipolytic response to epinephrine was greater (P less than 0.05) on day 4 than day 1 in both groups of subjects. In conclusion, lipolysis during fasting is less completely suppressed by insulin and more readily stimulated by epinephrine. Abstract These studies were designed to determine whether the insulin resistance of fasting extends to its antilipolytic effects and whether fasting enhances the lipolytic effects ofadrenergic stimulation independent of changes in plasma hormone and substrate concentrations. Palmitate flux was determined isotopically (il-'4Cjpalmitate) before and during epinephrine infusion in normal volunteers after a 14-h (day 1) and an 84-h (day 4) fast. Using a pancreatic clamp, constant plasma hormone and glucose concentrations were achieved on both study days in seven subjects. Six subjects were infused with saline and served as controls. During the pancreatic clamp, palmitate flux was greater (P < 0.01) on day 4 than day 1, despite similar plasma insulin, glucagon, growth hormone, cortisol, epinephrine, norepinephrine, and glucose concentrations. The lipolytic response to epinephrine was greater (P < 0.05) on day 4 than day 1 in both groups of subjects. In conclusion, lipolysis during fasting is less completely suppressed by insulin and more readily stimulated by epinephrine.
Introduction
The orderly, increased release of free fatty acids (FFA) into the circulation during fasting provides an important alternative fuel to glucose for most body tissues. It is likely that the decrease in plasma insulin concentration that occurs during fasting is involved in regulating lipolysis, since insulin is a potent antilipolytic hormone, even at relatively low plasma concentrations (1) . In addition, decreased adipose tissue sensitivity to insulin could play a role. Although fasting is known to induce resistance to insulin's ability to stimulate glucose utilization (2) , it remains controversial whether its antilipolytic properties are also affected (3) (4) (5) .
In addition to insulin, adrenergic mechanisms regulate FFA availability (6) . In human adipocytes, fl,-adrenergic receptors mediate stimulation of lipolysis by catecholamines and a2-adrenergic receptors mediate inhibition of lipolysis (7) (8) (9) . f3-adrenergic mechanisms appear to predominate both in vitro (8) and in vivo; infusions of mixed a-and fl-adrenergic agonists such as epinephrine result in increased lipolysis as evidenced by increments in the circulating levels of FFA and glycerol and increments in FFA appearance rates (6) . Fasting has been reported to increase adipocyte fl-adrenergic receptor numbers in rats (10) but to decrease fl-adrenergic receptor number in some human adipose tissue sites (1 1). Adipocytes from calorically restricted or fasting humans exhibit increased basal lipolytic rates but decreased lipolytic (indeed even antilipolytic) responses to epinephrine and norepinephrine (10 -16) . The increase in basal lipolysis and reversal ofthe effect ofepinephrine can be mimicked in vitro by removal of endogenous adenosine (16) , suggesting that the changes associated with fasting are the result ofdecreased inhibition of lipolysis by local modulators (16, 17) . Clearly, these in vitro findings do not explain the mechanisms of increased basal and catecholamine-stimulated lipolysis (18) (19) (20) (21) in vivo during fasting. Lower ambient insulin secretion could explain both increased basal and catecholamine-stimulated lipolysis (22). In addition, increments in lipolytic hormones, such as growth hormone (23) and glucagon (24) , as well as the catecholamines, could explain increased lipolysis, since their plasma concentrations are increased during fasting (25) . If these hormonal adaptations are solely responsible for increased lipolysis during fasting, the latter should be reversed if the hormone concentrations were adjusted experimentally to pre-fast levels during fasting.
The following studies were undertaken to test the hypotheses that fasting in normal humans both reduces insulin's antilipolytic potency and enhances the lipolytic effect of epinephrine in vivo when plasma glucose, insulin, glucagon, growth hormone, epinephrine, and norepinephrine concentrations are identical.
Methods
Subjects. Informed written consent was obtained from 13 The design is outlined in Fig. 1 . The subjects remained hospitalized in the Clinical Research Center through completion of the study, where they had free access to water but were not allowed to eat. Urinary ketones
were measured 4 to 6 times daily to monitor compliance with the fast. On the morning of each study, a 19-gauge scalp vein needle was inserted into a dorsal hand vein in a retrograde fashion and the hand was placed in a heated (50'-550C) box for sampling ofarterialized blood as previously described (26) (27) . A "pancreatic clamp" was begun at minute 0 (somatostatin, 200 ug/h; growth hormone, 4 ng/kg'l/min-'; glucagon, 0.6 ng/kg-'/min-'; and insulin, 0.20 mU/kg'I/min-). (These studies were completed before the announcement of potential viral contamination of National Pituitary Agency human growth hormone). The hormones were suspended in 0.9% NaCl containing 1% human serum albumin and infused via a Harvard Pump. An intravenous bolus of 0.14 mU/kg of insulin was given at minute 0 and variable amounts of glucose infused with a Harvard pump to maintain the plasma glucose concentration constant at 85 mg/ dl in all subjects, as previously described (27) . Because the plasma glucose concentrations were appreciably lower after 84 h of fasting, increased amounts of glucose were infused during the first 15-30 min of the pancreatic clamp on day 4 to increase the plasma glucose concentrations to 85 mg/dl. Blood was sampled from the pancreatic clamp subjects at 15-min intervals from minute 0 to +270 and assayed immediately for plasma glucose concentration. From minute 180 to 270 minutes, subjects were infused with epinephrine-diluted 0.9% saline containing ascorbic acid(I mg/ml) at a rate of 13 ng/kg'/min-'. In the second group ofexperiments, six subjects were studied in an identical fashion except they received an infusion ofsaline in place of the pancreatic clamp and served as controls.
Blood was sampled before starting the isotope infusion on each day and assayed for palmitate specific activity ( (29) . Plasma insulin (30) , C-peptide (31) , glucagon (32), growth hormone (33) , epinephrine, and norepinephrine (34) concentrations were determined at -30, -15, 0, +150, +165, +180, +240, +255, +270 min.
Plasma palmitate sp act and concentration were determined by a high performance liquid chromatography technique recently developed in our laboratory (29) , with the exception that [9,_0-3H]palmitate was used as an internal standard. The coefficient of variation for replicate analysis using this procedure is 3.8% for concentration and 2.3% for specific activity.
Calculations
Minute -45 to O will be referred to as the "baseline" study period; minute 135 to 180 as the "clamp" study period for subjects undergoing the 1. Abbreviation used in this paper: sp act, specific activity. pancreatic clamp, and "saline" study period for control subjects; and minute 195 to 270 as the "epinephrine" study period. Since plasma hormone concentrations were stable during each study period, the average values for each study period were determined for each subject and used to calculate the group mean and standard error.
Plasma palmitate concentrations and specific activities were nearly constant during the baseline study period and the third hour of the clamp or saline study periods; therefore, steady state conditions were assumed. Palmitate flux was calculated for each individual during these study periods using mean specific activity and the standard formula: During the epinephrine infusion, palmitate sp act and concentrations were not constant. Recent studies performed in our laboratory (29) have shown that when FFA flux is changing, the best estimate of rate of appearance at a given sampling time is provided by the steady state equations described above. Therefore, the lipolytic response to epinephrine was assessed by calculating the palmitate rate of appearance at 15-min intervals during the epinephrine infusion, and determining both the area under the curve of palmitate rate of appearance above baseline and the peak increment in palmitate rate of appearance. Because of blood volume sampling limitations, palmitate sp act and concentration were not determined at minute 195 in clamp subjects.
All results are expressed as mean±SE. Statistical comparisons between the same study periods on day I vs. day 4 in the same group were determined using a two-tailed paired Student's t test, as were comparisons between one time interval and another on the same study day. Comparisons between groups at the same time intervals were made using a two-tailed nonpaired Student's t test.
Results
Baseline hormone and substrate concentrations, FFA, and palmitateflux (Table I) . As expected, after 84 h of fasting, plasma concentrations of glucose decreased (P < 0.001) while those of palmitate, total FFA, and ketone bodies increased (all P <0.001). (Table II) . In the control group, plasma concentrations of insulin, C-peptide, glucagon, and growth hormone did not change significantly between baseline and saline study periods on either day 1 or day 4. During the pancreatic clamp, the chosen insulin infusion rate resulted in plasma insulin concentrations of -12 uU/ml on both study days, which were not significantly different from each other. Plasma concentrations of growth hormone and glucagon did not change from basal values when the pancreatic clamp was instituted on day 1, and were similar during the clamp periods on days 1 and 4.
Plasma catecholamine concentrations (Table II) . On days 1 and 4, plasma epinephrine and norepinephrine concentrations increased slightly, but not significantly, between baseline and saline study periods in the control subjects; a similar trend was noted on day 1 between baseline and clamp study periods in subjects undergoing the pancreatic clamp. However, during the day-4 pancreatic clamp, plasma epinephrine and norepinephrine concentrations decreased to values not significantly different from those observed during the day-I clamp study period (56±8 vs. 88±23 pg/ml and 234±17 vs. 229±26 pg/ml, respectively). The decline in plasma norepinephrine concentrations was statistically significant. During the intravenous epinephrine infusions, plasma epinephrine and norepinephrine concentrations were not different between groups or between study days.
FFA response to clamp and saline. When plasma insulin concentrations were increased, but plasma glucagon and growth hormone concentrations maintained constant during the pancreatic clamp on day 1, plasma concentrations of ketone bodies (data not shown), total FFA, and palmitate (Fig. 2) decreased. Palmitate sp act increased (Fig. 2) and remained stable during the third hour ofthe pancreatic clamp. On day 4 the same pattern of changes was observed (Fig. 2) ; however, plasma palmitate concentration and flux during the third hour of the clamp remained higher (P < 0.01) on day 4 than day 1 ( kg-'/min-').
Glucose and hormone responses to epinephrine infusion. During the 90-min epinephrine infusion in subjects undergoing the pancreatic clamp, no changes occurred in plasma concentrations ofglucose, insulin, C-peptide, glucagon, or growth hormone relative to the clamp study period on either day 1 or day 4 . On day 1, in the saline-infused control subjects, epinephrine infusion resulted in increased plasma concentrations of glucose (93±3-106±5, P < 0.01) and insulin (P < 0.005) (Table II) , while those of glucagon and growth hormone did not change significantly. On day 4, plasma glucose concentrations increased (P < 0.05) from 61±2 to 67±3 mg/dl), as did those of insulin (P < 0.005) and glucagon (P < 0.05), while that of growth hormone decreased (P < 0.05) (Table II) .
FFA responses to epinephrine infusion. During the epinephrine infusion, plasma palmitate and total FFA concentrations increased, palmitate specific activity decreased, and palmitate rate of appearance increased in all subjects (Figs. 3 and 4) . In control subjects, a greater (P < 0.05) lipolytic response to epinephrine was observed on day 4 Heart rate response to epinephrine infusion. No subjective responses to epinephrine were reported by any of the subjects on day 1 ofthe study, and little change in heart rate was observed (an increase of 5±1 beats/min). On day 4, however, 9 of 11 subjects reported symptoms of adrenergic stimulation, including forceful heart beat, tremulousness, and nervousness. They were also found to have greater increases in heart rate (A = + 15±3 beats/min, P < 0.05 vs. day 1). These symptoms always occurred between 15 and 45 min after beginning the epinephrine infusion and were resolved within 15 to 30 min despite continued infusion of epinephrine. In two subjects, plasma catecholamine concentrations were measured 15 and 30 min after beginning the epinephrine infusion on both study days, to ensure that they were not higher during the symptomatic time interval; the values were identical to those observed between 60 and 90 min of the epinephrine infusion (data not shown).
Discussion
The purpose of these studies was to determine whether fasting in normal humans results in resistance to insulin's antilipolytic subjects. These data provide strong evidence of fasting-induced insulin resistance with regards to lipolysis. Intravenous epinephrine infusion after 84 h offasting resulted in greater increases in palmitate flux than after 14 h of fasting in both the salineinfused and pancreatic clamp subjects. Therefore, the fastingenhanced lipolytic response to epinephrine infusion cannot be accounted for solely by changes in plasma glucose and hormone concentrations.
The finding of fasting-induced insulin resistance with regards to lipolysis is consistent with the conclusions of Cahill et al. (3) , but at variance with those of two more recent studies (4, 5) involving insulin administration to humans before and after fasting. In these two studies (4, 5) , the antilipolytic activity of insulin was assessed as the decrease in plasma FFA concentrations from baseline, whereas the present study compares the absolute FFA flux at a given insulin concentration before and after fasting. The latter approach was selected because of the vastly differing hormone and substrate concentrations before and after fasting, and because of the inherent difficulties in comparing changes from baseline (35) . The finding that greater amounts of circulating FFA are present after fasting under conditions of identical insulin concentrations supports the concept of fasting-induced insulin resistance with regards to lipolysis.
This conclusion also appears to be at variance with in vitro studies suggesting that fasting enhances insulin's antilipolytic properties (36) (37) (38) (39) (40) , perhaps via increased high affinity adipocyte insulin receptor binding (38) (39) (40) . The study of obese subjects (36) (37) (38) (39) (40) , a longer duration of fasting (36) (37) (38) (39) (40) , and regional differences in the response of adipocytes to various lipolytic and antilipolytic stimuli (15, 36, 37, 40 ) may provide partial explanations for the apparent discrepancy between those studies and the present report. The most likely explanation for the different conclusions, however, are differences in data interpretation and perspective. In vitro studies have demonstrated marked increases in basal lipolysis after fasting and define insulin responsiveness as the decrease in glycerol release from basal values, either in relative or absolute terms (39, 40) . The amount of glycerol released at the maximally suppressive insulin concentration was greater after fasting, even though the decrement from basal was greater (39, 40 (I12-14) . Increased fl-adrenergic responsiveness has also been observed (13) . The findings of the present study suggest that in fasting nonobese individuals the net change in a-and fl-adrenergic effects is in favor ofincreased fl-adrenergic responsiveness. Possible explanations for the different conclusions include the relatively greater amounts of catecholamines used in the in vitro studies, regional differences in adipocyte response to catecholamines, and the study of obese, as opposed to nonobese, subjects.
Plasma epinephrine and norepinephrine concentrations were higher in our subjects on day 4 of fasting than on day 1, consistent with the findings of others (43, 44) . Sodium depletion has been purported to account for the higher plasma catecholamine concentrations observed after fasting (43) , since plasma catecholamine concentrations and urinary catecholamine excretion actually decline in sodium-replete subjects during caloric restriction (45) . Fasting has been shown to reduce sympathetic neural activity in rodents (44 (44) .
The enhanced lipolytic and chronotropic responses to epinephrine after fasting were also somewhat surprising, considering that an increase in plasma hormone concentrations (in this case, catecholamines) usually results in down-regulation of receptors (46) . If, however, autonomic nervous system activity decreases during fasting (44), up-regulation of postsynaptic adrenergic re-ceptors may actually occur, which might then allow greater stimulation by the epinephrine administered during this study.
It is conceivable that fasting may alter the clearance ofinsulin (19) , glucagon (47), growth hormone, or epinephrine. However, when endogenous release of insulin, glucagon, and growth hormone was inhibited with somatostatin and these hormones infused on a body weight basis, their plasma concentrations did not differ, indicating that the clearance of these hormones was not significantly altered by fasting. Since infusion of epinephrine may have resulted in differing suppression of endogenous epinephrine release, an equally firm conclusion cannot be reached concerning epinephrine clearance during fasting. However, the increment in plasma epinephrine concentrations was virtually identical on days 1 and 4, suggesting that no change in epinephrine clearance occurred.
In summary, the present studies demonstrate that the accelerated lipolysis of short-term fasting is less completely suppressed by an identical insulin infusion, even when plasma concentrations of glucose, glucagon, and growth hormone (as well as epinephrine) are adjusted to levels comparable to prefasting values. In addition, lipolysis during fasting is more readily stimulated by epinephrine, an observation that cannot be attributed solely to changes in plasma hormone and substrate concentrations. Increased adipocyte sensitivity to fl-adrenergic stimulation, in concert with decrements in insulin and increments in epinephrine concentrations, may facilitate FFA mobilization during fasting.
